A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Seven strategies that could help curb opioid addiction among Medicaid beneficiaries

by Susan Levine, specialist leader, strategy and operations at Deloitte Consulting LLP

Opioid addiction has deep roots in the United States. During the Civil War, the Union Army issued nearly 10 million opium pills and nearly 3 million ounces of opium powder.1 Injured soldiers who were given opium for the pain sometimes returned home as addicts. The current opioid epidemic has similar origins—liberal opioid prescribing for pain has led to an epidemic of addiction.

Read more

Can human-centered design bring more humanity into health care?

by Ben Jonash, Principal, Deloitte Consulting LLP

The words “putting patients first”—or some variation—can be seen on the walls or in the promotional literature of nearly every health care company in the country. I don’t question the intent, but if we are going to help solve health care’s most entrenched challenges, this idea should be at the heart of our business.

Human-centered design is a mindset and discipline that puts the person,

Read more

Is your state’s Medicaid program ready for value-based care? Here are six things to consider.

by Jeff Burke, Senior Manager Deloitte Consulting LLP and Matt Siegel, Specialist Leader, Deloitte Consulting LLP

In our last blog, we profiled several states that are transitioning their Medicaid programs to value-based care models. As we noted, some states are likely better prepared for the change than others. But how can states know if they are ready to “walk-the-walk” down the value-based care path?

Medicaid program leaders should first consider assessing readiness.

Read more

CMS’s updated quality evaluation formula leads to more 5-star hospitals

by Randolph Gordon, MD, MPH, Director, Deloitte Consulting LLP

The number of top-rated hospitals in the US quadrupled—from 83 to 337—after the US Centers for Medicare and Medicaid Services (CMS) revised the methodology behind its Hospital Quality Star Rating system. At the same time, twice as many hospitals landed on the low end of the ratings spectrum.1

Under the revised methodology, which CMS implemented in December,

Read more

As biosimilars enter the US market, will they be used, and can they reduce spending?

by Erik D. Smith, Ph.D., and Tom Yang, Ph.D., Deloitte Consulting, LLP

Last fall, the Food and Drug Administration (FDA) approved the first biosimilar to treat multiple types of cancer.i While biosimilars have tremendous potential, there also is a good bit of uncertainty around them, particularly in oncology where biologics can have a predominant role in treatment.

February is National Cancer Prevention Month, which gives us a nice opportunity to explore the role biosimilars could play in preventing and treating cancer.

Read more

Could 2018 be the year of the Medicaid ACO?

by Jeff Burke, Senior Manager Deloitte Consulting LLP and Matt Siegel, Specialist Leader, Deloitte Consulting LLP

A constant among many Medicaid programs is concern over rising costs. This applies to the 32 states that expanded their programs under the Affordable Care Act (ACA), and those that didn’t. In response, a growing number of states are eyeing alternative payment models (APMs), which reward health care providers for the value they offer, rather than the number of tests and services they perform.

Read more